Skip to search formSkip to main contentSkip to account menu

gp100:209-217(210M) peptide vaccine

Known as: G9 209-2M, gp100:209-217(210M) 
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Efforts to develop effective cancer vaccines often use combinations of immunogenic peptides to increase the applicability and… 
Highly Cited
2004
Highly Cited
2004
Successful immunotherapy with peptide vaccines depends on the in vivo generation of sufficient numbers of anti-tumor T cells with… 
Highly Cited
2002
Highly Cited
2002
The functional status of circulating vaccine-induced, tumor-specific T cells has been questioned to explain their paradoxical… 
Highly Cited
2000
Highly Cited
2000
Selective blunting of the status of activation of circulating tumor-specific T cells was invoked to explain their paradoxical…